
A US jury found on Thursday that Credit Suisse did not conspire with the world’s largest banks to rig prices in the foreign exchange market between 2007 and 2013, handing the bank a win as it works to restructure and put a string of scandals behind it.
The case stems from the forex rigging scandal, which led to international regulatory probes resulting in more than $10 billion in fines for several banks.
Related: Credit Suisse Agrees To Settle US Antitrust Suit
A Credit Suisse spokesperson said the bank is “extremely pleased that the jury agreed with us that plaintiffs’ case had no merit.”
Credit Suisse was the last bank defendant remaining in the class action brought by currency investors in 2013, after 15 others reached settlements worth $2.31 billion. The investors alleged that Credit Suisse traders shared nonpublic pricing information with traders at other banks.
During the trial in Manhattan federal court which began on Oct. 11, jurors heard testimony that in 2015 five banks had pleaded guilty to forex-related antitrust conspiracies, and saw transcripts from chat rooms with names such as “The Cartel” where investors said traders colluded.
The jury began deliberations on Wednesday and worked for a total of around seven hours to reach their verdict. They found that investors had proved there was a conspiracy to rig prices in the forex market, but not that it involved Credit Suisse.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas